促销时间表 Aurinia Pharmaceuticals Inc.
先进的时间表
简单图表
关于公司 Aurinia Pharmaceuticals Inc.
Биофармацевтическая компания Aurinia Pharmaceuticals Inc. разрабатывает и коммерциализирует методы лечения различных заболеваний, при которых медицинские потребности не удовлетворяются в Японии и Китае. Компания предлагает ЛУПКИНИС для лечения взрослых пациентов с активным волчаночным нефритом. У нее есть соглашение о сотрудничестве и лицензионное соглашение с Otsuka Pharmaceutical Co., Ltd. Штаб-квартира компании находится в Виктории, Канада.| IPO date | 1999-01-26 |
|---|---|
| ISIN | CA05156V1022 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | https://www.auriniapharma.com |
| Цена ао | 8.5 |
| 每日价格变化: | -2.02% (8.67) |
|---|---|
| 每周价格变化: | +1.49% (8.37) |
| 每月价格变化: | +5.53% (8.05) |
| 3个月内价格变化: | -5.4% (8.98) |
| 六个月内的价格变化: | +18.65% (7.16) |
| 每年价格变化: | +69.9% (5) |
| 3年内价格变化: | -28.73% (11.92) |
| 5年内价格变化: | -39.84% (14.12) |
| 年初以来价格变化: | -5.4% (8.98) |
|
|
低估
|
效率
|
|||||||||||||||||||||||||||||||||||||
股息
|
责任
|
成长冲动
|
|||||||||||||||||||||||||||||||||||||
| 机构 | 体积 | 分享, % |
|---|---|---|
| Armistice Capital, LLC | 12 | 8.59 |
| Blackrock Inc. | 9 | 6.07 |
| NEA Management Company, LLC | 4 | 2.78 |
| State Street Corporation | 3 | 1.94 |
| Goldman Sachs Group Inc | 2 | 1.51 |
| Nuveen Asset Management, LLC | 2 | 1.44 |
| Tang Capital Management, LLC | 2 | 1.44 |
| Geode Capital Management, LLC | 2 | 1.12 |
| Vanguard Group Inc | 2 | 1.07 |
| Morgan Stanley | 1 | 0.91 |
| ETF | 分享, % | 本年盈利能力, % | 股息, % |
|---|---|---|---|
| Future Tech ETF | 0.10135 | 426.34 | 0.8416 |
| Principal Healthcare Innovators ETF | 0.10135 | 618.5 | 0.8416 |
iShares Russell 2000 Growth ETF
|
0.05241 | 38.04 | 0.6026 |
| iShares Morningstar Small-Cap Growth ETF | 0.02593 | 33.63 | 0.72598 |
| iShares Morningstar Small-Cap Growth ETF | 0.02593 | 587.89 | 0.72598 |
| iShares Morningstar Small-Cap ETF | 0.02128 | 391.25 | 1.60498 |
| iShares Morningstar Small-Cap ETF | 0.02128 | 30.1 | 1.60498 |
| iShares Morningstar Small Cap Value ETF | 0.01584 | 26.7 | 2.50476 |
| iShares Morningstar Small-Cap Value ETF | 0.01584 | 201.65 | 2.50476 |
| iShares Russell 3000 ETF | 0.00184 | 24.83 | 1.43482 |
| 0.04 | 237.89 | 1.34 |
| 导师 | 职称 | 支付 | 出生年份 |
|---|---|---|---|
| Mr. Peter S. Greenleaf M.B.A. | President, CEO & Director | 1.34M | 1970 (55 年) |
| Mr. Matthew Maxwell Donley M.B.A. | Executive Vice President of Operations & Strategy | 811.82k | 1969 (56 年) |
| Mr. Stephen P. Robertson | Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer | 739.68k | 1982 (43 年) |
| Mr. Michael R. Martin | Chief Business Officer | 350.57k | 1972 (53 年) |
| Mr. Joseph M. Miller CPA | Chief Financial Officer | 791.92k | 1974 (51 年) |
| Ms. Sue Evans | Senior Vice President of Global Regulatory Affairs | N/A | |
| Mr. Scott Habig | Chief Commercial Officer | N/A | 1960 (65 年) |
| Ms. Andrea Levin Christopher | Head of the Corporate Communications & Investor Relations | ||
| Dr. Gregory F. Keenan M.D. | Chief Medical Officer | ||
| Dr. Ann M. Daus Ph.D. | Senior Vice President of Quality |
地址: Canada, Victoria, BC VZ X, 4464 Markham Street - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.auriniapharma.com
网站: https://www.auriniapharma.com
